Simulations Plus, Inc. (SLP)
NASDAQ: SLP · Real-Time Price · USD
19.07
-0.98 (-4.89%)
At close: Jun 13, 2025, 4:00 PM
19.30
+0.23 (1.21%)
After-hours: Jun 13, 2025, 4:14 PM EDT
Simulations Plus Revenue
Simulations Plus had revenue of $22.43M in the quarter ending February 28, 2025, with 22.55% growth. This brings the company's revenue in the last twelve months to $78.56M, up 21.49% year-over-year. In the fiscal year ending August 31, 2024, Simulations Plus had annual revenue of $70.01M with 17.52% growth.
Revenue (ttm)
$78.56M
Revenue Growth
+21.49%
P/S Ratio
5.12
Revenue / Employee
$318,073
Employees
247
Market Cap
383.52M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Aug 31, 2024 | 70.01M | 10.44M | 17.52% |
Aug 31, 2023 | 59.58M | 5.67M | 10.52% |
Aug 31, 2022 | 53.91M | 7.44M | 16.01% |
Aug 31, 2021 | 46.47M | 4.88M | 11.73% |
Aug 31, 2020 | 41.59M | 7.62M | 22.43% |
Aug 31, 2019 | Pro | Pro | Pro |
Aug 31, 2018 | Pro | Pro | Pro |
Aug 31, 2017 | Pro | Pro | Pro |
Aug 31, 2016 | Pro | Pro | Pro |
Aug 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SLP News
- 8 hours ago - Simulations Plus: Further Downside Is Likely (Rating Downgrade) - Seeking Alpha
- 1 day ago - Simulations Plus Slashes Guidance Amid Biotech Spending Cuts, Analyst Expresses Doubt - Benzinga
- 1 day ago - Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum - Business Wire
- 2 days ago - Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue - Business Wire
- 8 days ago - Simulations Plus Releases ADMET Predictor® 13 - Business Wire
- 4 weeks ago - Simulations Plus Releases DILIsym® 11 - Business Wire
- 7 weeks ago - Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies - Business Wire
- 2 months ago - Simulations Plus: Benefiting From FDA Modernization And AI - Seeking Alpha